Clinical Trials Logo

Cardiovascular Disease clinical trials

View clinical trials related to Cardiovascular Disease.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT03882645 Terminated - Clinical trials for Cardiovascular Disease

Chinese Heart Healthy Diet for People With High Cardiovascular Risk in China (DECIDE-Diet)

Start date: March 22, 2019
Phase: N/A
Study type: Interventional

The DECIDE - Diet (Diet, ExerCIse and carDiovascular hEalth - Chinese Heart Healthy Diet for People With High Cardiovascular Risk in China) is to evaluate the effects of CHH-diet in reducing blood pressure in Chinese people with high cardiovascular risk. The study will recruit 360 adults people from 4 centers in China. All eligible participants will participate in a 1-week run-in phase in which they are fed the usual Chinese diet. Participants who pass the run-in phase will be randomly assigned 1:1 to receive CHH-diet or usual diet with the use of a central concealed randomization procedure (simple randomization), stratified by center and batch. The intervention will last 28 days. Primary outcome will be the change in systolic blood pressure. The secondary outcomes include the differences between the two groups in the changes of diastolic blood pressure, total cholesterol, fasting blood glucose, 10-year CVD risk, gut microbial community and food preference score.

NCT ID: NCT03174522 Terminated - Clinical trials for Diabetes Mellitus, Type 2

The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM

Start date: April 25, 2017
Phase: Phase 3
Study type: Interventional

This trial is a pivotal, placebo-controlled, double-blind, parallel-group, adaptive trial conducted in subjects with DM and CLI Rutherford Category 5. Minimisation will be used to assign eligible subjects in a 2:1 ratio to receive a single intra-arterial administration of REX-001 or matching placebo into the index limb.

NCT ID: NCT03111238 Terminated - Clinical trials for Diabetes Mellitus, Type 2

The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM

Start date: April 5, 2017
Phase: Phase 3
Study type: Interventional

This trial is a pivotal, placebo-controlled, double-blind, parallel-group, adaptive trial conducted in subjects with DM and CLI Rutherford Category 4. Minimisation will be used to assign eligible subjects in a 2:1 ratio to receive a single intra-arterial administration of REX-001 or matching placebo into the index limb.

NCT ID: NCT02845063 Terminated - Clinical trials for Cardiovascular Disease

Effect of ACE Genotype on Cardiovascular Rehabilitation

ACE-REHAB
Start date: May 1, 2016
Phase: Phase 2
Study type: Interventional

The study aims to systematically investigate the interaction between training modality, ACE genotype and disease in heart patients whom complete a cardiovascular rehabilitation program. This is carried out with the goal to improve the benefit of cardiovascular rehabilitation for the patient by maximising adjustments in muscle structure and function with the intervention. A population of healthy individuals will be recruited who will carry out the same training program, in order to compare the training effects respective to the general population.

NCT ID: NCT02765516 Terminated - Clinical trials for Cardiovascular Disease

Genetic Basis for Prediction of Non-responders to Dietary Plant Sterol Intervention

GenePredict-PS
Start date: July 5, 2017
Phase: N/A
Study type: Interventional

The objective of this study is to utilize information on associations between genetic predisposition pertaining to multiple single nucleotide polymorphisms (SNPs) and the degree of responsiveness of low-density lipoprotein cholesterol (LDL-C) lowering to plant sterols (PS). The predictive potential of SNPs associated with PS responsiveness will be evaluated using a randomized human intervention trial examining responsiveness of lowering blood LDL-C levels to PS intervention.

NCT ID: NCT02740699 Terminated - Clinical trials for Cardiovascular Disease

CT COMPARE: CT Coronary Angiography to Measure Plaque Reduction

Start date: April 11, 2016
Phase: Phase 4
Study type: Interventional

Background: Coronary artery disease causes plaque in arteries. This can cause stroke or heart disease. Drugs called statins might shrink plaque. Researchers want to study how CT scanning can determine if an individuals arterial plaque has decreased while taking statins. Objectives: To measure the change in coronary artery plaque volume in people treated with high-intensity statin therapy using CT and MRI scans. To study the metabolic activity of plaque in arteries. To determine how well plaque measurements from heart CT scans can be replicated. Eligibility: Men ages 40-75 and women ages 40-75 who are good candidates for statin treatment Design: Visit 1: participants will be screened with: - Medical history - Blood tests - Heart MRI and CT scan: An IV inserted into an arm or hand vein removes blood and injects contrast, and medicine if needed. Participants lie on a table that slides into a machine that takes pictures of the body. For the CT scan, if their heart rate is too high, they get medicine to lower it. They breathe in a special way, holding their breath for 5 seconds. Participants will begin high-intensity statin treatment. Participants will have 7 more visits over 3 years. All visits include blood tests and medication review. Some may also include: - Statin treatment adjustment - CT scan - MRI scan - Physical exam Participants may join the PET Substudy. This includes 5 more visits during the study. These include: - Getting an IV in an arm vein - Blood tests - PET scans: They fast 12 hours before. Participants may join the Reproducibility Substudy if they had a slow heart rate during their first CT scan. This includes 1 additional heart CT scan 4 weeks later.

NCT ID: NCT02712372 Terminated - Clinical trials for Cardiovascular Disease

A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects

Start date: June 2016
Phase: Phase 1
Study type: Interventional

This is a Phase I, first-in-human (FIH) study to assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of AZD4831 after single and multiple ascending doses in healthy male subjects

NCT ID: NCT02573116 Terminated - Clinical trials for Cardiovascular Disease in Obstructive Sleep Apnea

Impact of Treatment of Periodontis on Endothelial Function in Patients With Obstructive Sleep Apnea

EndothSAS
Start date: March 24, 2014
Phase: N/A
Study type: Interventional

Evaluation of the add-on effect on endothelial dysfunction of treatment of periodontitis in patients with chronic periodontitis and severe obstructive sleep apnea treated by CPAP. Patients with and without chronic periodontitis will be treated by CPAP for 20 weeks. At V2 (10 weeks), endothelial dysfunction will be assessed by the Reactive Hyperemia- Peripheral Artery Tone index. The endothelial dysfunction of the patients will be also assessed at V3 (20 weeks) after periodontitis treatment for the group of patients with chronic periodontitis.

NCT ID: NCT02561507 Terminated - Surgery Clinical Trials

Perioperative Aspirin Usage Survey

Start date: October 2015
Phase:
Study type: Observational

This is a survey of members of the American College of Surgeons (ACS), to describe and explore current patterns of their decisions about withholding or continuation for patients taking aspirin (ASA) in the perioperative period. Secondarily, the survey will also explore surgeons' knowledge about the risks and benefits attending this decision, and about national organizations' recommendations.

NCT ID: NCT02524106 Terminated - Clinical trials for Cardiovascular Disease

Bococizumab HIV Evaluation (B-HIVE) Study

B-HIVE
Start date: August 2016
Phase: Phase 3
Study type: Interventional

B-HIVE is a Phase 3, double blind, placebo-controlled, randomized, parallel group study, designed to compare the efficacy and safety of bococizumab 150 mg subcutaneously every 2 weeks to bococizumab placebo subcutaneously every 2 weeks for LDL-C lowering in HIV-infected subjects.